JP Morgan Chase
BCRX icon

JP Morgan Chase’s BioCryst Pharmaceuticals BCRX Stock Holding History

JP Morgan Chase’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-295,000
Closed -$3.39M – 6689
2022
Q4 		$3.39M Buy
+295,000
New +$3.68M ﹤0.01% 3146
2019
Q3 		– Sell
-35,000
Closed -$127K – 5718
2019
Q2 		$127K Buy
+35,000
New +$211K ﹤0.01% 4837
2019
Q1 		– Sell
-90,000
Closed -$726K – 5757
2018
Q4 		$726K Sell
90,000
-3,500
-4% -$27.2K ﹤0.01% 3931
2018
Q3 		$713K Buy
+93,500
New +$628K ﹤0.01% 4104
2017
Q2 		– Sell
-104,200
Closed -$875K – 4957
2017
Q1 		$875K Buy
104,200
+100,000
+2,381% +$696K ﹤0.01% 3468
2016
Q4 		$27K Buy
+4,200
New +$21.9K ﹤0.01% 4653

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

JP Morgan Chase's BCRX Position: Q2 2026 in Review

JP Morgan Chase reduced its BioCryst Pharmaceuticals (BCRX) stake by 66% in Q2 2026, selling an estimated $9.19M and leaving 525,449 shares worth $5.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3432.

JP Morgan Chase first reported a position in BCRX in Q2 2013 and has held it in 44 quarters since. The position peaked at $14.6M in Q1 2026. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • JP Morgan Chase held 525,449 shares of BioCryst Pharmaceuticals worth $5.12M as of Q2 2026.
  • JP Morgan Chase sold 1,016,529 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $9.19M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3432 holding.
  • JP Morgan Chase first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • JP Morgan Chase's BioCryst Pharmaceuticals position peaked at $14.6M in Q1 2026.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.